Drawing for EXPRES2ION

USPTO serial 79159531

EXPRES2ION

Reviewed by CopyMark Law Group

Reg. 4893901Status 404
Filing date
Status date
Registration date
Feb 2, 2016
Examiner
DESAI, BRIN ANDERSON
Law office
GENERIC WEB UPDATE

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EXPRES2ION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

George S. Pavlik

George S. Pavlik Levenfeld Pearlstein, LLC120 S. Riverside PlazaSuite 1800Chicago, IL 60606

Goods and services

ClassDescriptionStatusFirst use
001Biological reagents for scientific and research purposes; biological and chemical preparations for use in biotechnology, namely, [ oligonucleotides, DNA primers, synthetic oligonucleotides, assays, and ] reagents for use in genetic and proteomics research; [ chemicals and polymers other than for medical or veterinary use for use in separation, binding and purification of biological and chemical materials; chemicals, namely, solid phases other than for medical or veterinary use for use in separation, binding and purification of biological and chemical materials; ] reagents containing ligands, effector molecules and antibodies for scientific and medical research use; [ antibody-conjugated micro-beads and antibody-conjugated microspheres all for scientific and medical research use and for activation of immune system cells; ] chemicals, biochemicals and reagents for use in industry, science and research; [ chemical compositions for scientific and industrial use in the preparation of culture media; media for cell/tissue cultures, cell/tissue culture growth supplements, reagents and buffers for use in cell/tissue cultures, transfection reagents, cryopreservation reagents other than for medical or veterinary purposes; ] reagents containing proteins, ligands, effector molecules and antibodies for scientific or medical research use; biological and biochemical preparations for scientific or medical research use, namely, [ oligonucleotides, DNA primers, synthetic oligonucleotides, assays, and ] reagents for use in genetic and proteomics research; reagents and kits consisting of chemicals, biochemicals and reagents, all for scientific or research use; kits for scientific and research use consisting primarily of [ one or more of the following: proteins, nucleic acids, hormones, purification supports, resins, cells, gels, buffers, stains and associated ] reagents for the expression, amplification, purification and analysis of biological samples; protein and kits consisting primarily of [ oligonucleotides, peptide substrates, assays and ] reagents for use in genetic and proteomics research and for research purposes in biochemical laboratories; [ cell lines for use in scientific, laboratory, diagnostic and medical research; ] biological and chemical preparations for use in biotechnology, namely, [ oligonucleotides, DNA primers, synthetic oligonucleotides, assays, and ] reagents for use in genetic and proteomics research; chemical and biological products for use in medical science, namely, [ oligonucleotides, DNA primers, synthetic oligonucleotides, assays, and ] reagents for use in genetic and proteomics research; [ microbiological and tissue culture media, animal blood and serum, and reagents and kits consisting of chemicals, biochemicals, and reagents, all for scientific research; chemicals used for medical research purposes, namely, reagents containing proteins, ligands, effector molecules, and antibodies for medical research use; ] insect cells, insect cell culture media, and cell culture reagents all for medical laboratory use [ ; reagents and kits consisting of chemicals, biochemicals, and reagents, all for medical diagnostic laboratory use ]SECTION 70 - CANCELLED—
005[ Chemicals and polymers for medical or veterinary use for use in separation, binding and purification of biological and chemical materials; chemicals, namely, solid phases for medical or veterinary use for use in separation, binding and purification of biological and chemical materials; ] insect cells, insect cell culture media and cell culture reagents all for medical use [ ; pharmaceutical preparations and substances and therapeutic pharmaceuticals for use in the diagnosis, prophylaxis and treatment of cancers, infectious diseases, autoimmune diseases, ophthalmological diseases, metabolic diseases, respiratory diseases, cardiovascular diseases, genetic diseases, and central nervous system conditions; preparations and compositions for therapeutic use, namely, for activating cells of the immune systems; pharmaceutical preparations for use in the treatment of cancer, infectious diseases and immunodeficiencies; antibody-conjugated beads, antibody-conjugated micro-beads and antibody-conjugated microspheres for promoting a therapeutic effect on the body; biological and biochemical preparations for medical purposes for use in the diagnosis, prophylaxis and treatment of cancers, infectious diseases, autoimmune diseases, ophthalmological diseases, metabolic diseases, respiratory diseases, cardiovascular diseases, genetic diseases, and central nervous system conditions; microbiological and tissue culture media, animal blood and serum, and reagents and kits consisting of chemicals, biochemicals, and reagents, all for medical use; chemicals used for medical purposes, namely, reagents, proteins, cells, reagents containing proteins, ligands, effector molecules, and antibodies for medical use ]SECTION 70 - CANCELLED—
042[ Medical and scientific research; research and consultation services in the fields of pharmaceuticals, vaccines, medicine, biological sciences, immunotherapy, and medical devices; development of new products in the fields of pharmaceuticals, medicine, biological sciences, immunotherapy, and medical devices for others; scientific medical laboratory services; research and development for vaccines and new immunotherapy products for others; scientific and technological services, namely, research and design in the fields of medical diagnostics, vaccines, and pharmaceuticals; industrial analysis and research services in the fields of medical diagnostics, vaccines, and pharmaceuticals; research and development services all relating to science; research and development services all relating to industry in the fields of medical diagnostics, vaccines, and pharmaceuticals; research and development services all relating to science; research and development services all relating to biochemistry and biotechnology; research and development services all relating to products and tools to be used in biotechnical research or in biochemical research; ] laboratory research services in the field of gene cloning, gene expression, electrophoresis, protein purification and analysis, and protein interaction detection [ ; providing research data and other molecular biology information for molecular biology reagents and kits in the fields of science and research; scientific research and development; medical and scientific research in the field of molecular biology; biological research; biological cloning services; providing information on the subject of scientific research in the fields of biochemistry and biotechnology; scientific research in the fields of genetics and genetic engineering; biochemical research and development; chemical, biochemical, biological and bacteriological research and analysis; providing reagent sample testing and diagnostic services for others in the field of science and research related thereto; DNA screening for scientific purposes; genetic mapping for scientific purposes; genetic testing for scientific research purposes; providing scientific information via a web site that gives computer users the ability to upload and share video-based scientific protocols and other scientific-based videos; providing information in the field of molecular biology for scientific research purposes, also via on line searchable databases; providing scientific data in protein purification and analysis, and protein interaction detection; medical and scientific research for the development and commercialization of cell-based therapeutic immune system stimulators and enhancers with prophylactic and/or therapeutic purposes; technical research and consultation services in the fields of pharmaceuticals, medicine, biological sciences, immunotherapy, and medical devices; research and development for new immunotherapy products for others; biopharmaceutical research and development; scientific medical laboratory testing and diagnostic services for scientific research purposes; scientific research, namely, developing customized insect culture media, media formulations, and cell culture reagents, and evaluating culture media for others; contract scientific laboratory services and related consulting focused primarily on protein expressions, cell line development, and biotechnology upstream production process development ]SECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 8, 2024DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Oct 8, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 7, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Mar 17, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 17, 2023EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Mar 17, 2023EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Mar 17, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 17, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 30, 2022NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Aug 30, 2022C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Aug 16, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 15, 2022ES75TEAS SECTION 71 & 15 RECEIVED—
Feb 2, 2021REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Apr 16, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 10, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 10, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 15, 2016NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 8, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 4, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 4, 2016FIMPFINAL DISPOSITION PROCESSED—
May 2, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Feb 2, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 20, 2015GPNXNOTIFICATION PROCESSED BY IB—
Nov 17, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 17, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 4, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Nov 4, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Oct 28, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 14, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 8, 2015ALIEASSIGNED TO LIE—
Sep 10, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 8, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 8, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 8, 2015ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jul 7, 2015GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jul 7, 2015GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 7, 2015CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 12, 2015ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 12, 2015REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 12, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 12, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 12, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 13, 2015RFNTREFUSAL PROCESSED BY IB—
Feb 24, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 24, 2015RFRRREFUSAL PROCESSED BY MPU—
Feb 24, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 23, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 23, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 10, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 6, 2015DOCKASSIGNED TO EXAMINER—
Feb 6, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 5, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance